Signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
December 2002
2002:
December |
November |
October |
Other years: 2003 | 2004 | 2005 | 2006 | 2007 | 2008
News | News in brief | News Features
News
Stanford announces private plan to get stem-cell research moving
Stanford University in California is joining a growing list of US universities that are establishing privately funded stem-cell institutes.
Nature (19/26 December 2002)
| Full Text |
Mass resignation forces Italian rethink on university funds
A funding crisis has set off widespread protests at Italian universities last week — including the dramatic mass resignation of the leaders of all 72 Italian public universities.
Nature (19/26 December 2002)
| Full Text |
Canada stops Harvard's oncomouse in its tracks
The Canadian Supreme Court has turned down a far-reaching patent application on a genetically modified mouse — setting Canada's intellectual property law on a strinkingly independent path.
Nature (12 December 2002)
| Full Text |
Paper trail reveals references go unread by citing authors
Many of the references cited in scientific papers have not been read by the authors citing them, according to an analysis of how errors in citations propagate through the literature.
Nature (12 December 2002)
| Full Text |
Safety panel backs principle of gene-therapy trials
Clinical trials of a gene therapy for a rare disorder of the immune system should be allowed to continue in the United States, according to the panel that advises the NIH on the safety of gene transfer.
Nature (12 December 2002)
| Full Text |
Postdoc positions axed as economic crisis takes its toll
As many as 2,000 young German scientists are set to get a nasty shock in the mail as laboratories cancel planned positions in response to a budget freeze.
Nature (5 December 2002)
| Full Text |
Royal Institution's director blasts scientific sexism
The gloomy prognosis of young women's prospects in science arrived in a report from Susan Greenfield, director of the London-based Royal Institution of Great Britain.
Nature (5 December 2002)
| Full Text |
European Commission rethinks biotech patents
The European Commission (EC) has indicated that it is considering calling a halt to the granting of wide-ranging patents on human DNA sequences.
Nature Biotechnology (December 2002)
| Full Text |
Surprise US election results may boost biotech
Republican majorities in both branches of Congress give new impetus to the Bush agenda, and could boost momentum behind several federal initiatives or ongoing programs affecting the biotechnology industry.
Nature Biotechnology (December 2002)
| Full Text |
Japanese council urges reform of funding system
Japan's Biotechnology Strategy Council is likely to recommend large increases in government spending on life sciences research and biotechnology in its first report.
Nature Biotechnology (December 2002)
| Full Text |
Study critiques corporate control of trials
With the biotechnology and pharmaceutical industries reporting a record number of drugs in phase 3 clinical trials, a survey of US medical schools is critical of industry control over these trials.
Nature Biotechnology (December 2002)
| Full Text |
Mapping project moves forward despite controversy
On October 29, an international consortium announced the start of a $100 million, three-year project to construct a new type of map of the human genome.
Nature Medicine (December 2002)
| Full Text |
Review reopens old disagreements
Last month's publication of a review on the role of the immune system in tumor development has revealed a persistent divide between some groups of the cancer research community.
Nature Medicine (December 2002)
| Full Text |
Embryos to be treated as human subjects
The Bush Administration has revamped the charter of the federal advisory committee that addresses the safety of research volunteers, declaring that embryos used in research are 'human subjects' entitled to the same protections as fetuses, children and adults.
Nature Medicine (December 2002)
| Full Text |
Poor reports dog industry-academia liaison
Two new studies suggest that the relationship between academia and industry is not as healthy as it should be.
Nature Medicine (December 2002)
| Full Text |
FP6 brings bigger funds and some confusion
November 11 saw the long-awaited launch of Europe's Sixth Framework Program for Research (FP6), which will determine European Union research spending over the next five years.
Nature Medicine (December 2002)
| Full Text |
British government spending does not add up
The government office that funds biomedical research in Britain has been accused of misleading scientists over the true magnitude of a recently announced funding increase.
Nature Medicine (December 2002)
| Full Text |
News in brief
Britain drops initiative to explain science to the public
| Australia opens way to embryonic stem cells
| Germany sets new criteria for reinstated gene-therapy trials
| New trials for Erbitux
| US launches proteomic project
| US DHHS shuffles committees
News Features
2002 In context: Stem cells: Articles of faith adulterated
2002 saw researchers' faith in the healing power of adult stem cells sorely tested, as the cells' regenerative abilities became the focus of intense debate.
Nature (19/26 December 2002)
| Full Text |
Alliance for Cellular Signaling: Into unknown territory
The Alliance for Cellular Signaling is exploring new frontiers, both in fundamental scientific terms and in the way in which research in cell biology is conducted.
Nature (12 December 2002)
| Full Text |
Research materials: Share and share alike?
Producing a popular research tool will make you a lot of friends in science. But meeting requests to supply the material puts a heavy burden on your lab.
Nature (12 December 2002)
| Full Text |
The real deal
The human genome fired the public's imagination. But for many geneticists, the genome of their main experimental mammal — the mouse — is even more exciting. Nature's reporters sample the buzz in three leading laboratories.
Nature (5 December 2002)
| Full Text |
A forage in the junkyard
One of the main differences between the mouse and human genomes lies in the activity of 'junk' DNA sequences called retrotransposons. Carina Dennis considers what these sequences might be doing.
Nature (5 December 2002)
| Full Text |
Piecing it all together
The whole-genome shotgun method has assembled a high-quality draft mouse sequence. Future projects will wed the shotgun's speed and economy to established, map-based methods, says Declan Butler.
Nature (5 December 2002)
| Full Text |
|
